Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 22;36(11):2101–2112. doi: 10.1111/jdv.18409

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

(a) Sankey diagram of switches from a biologic and treatment discontinuation. *No other systemic treatment for 180 days or more. ^§Number of patients having switched to a biologic. Does not include patients who discontinued their biologic or participated in a clinical trial. Only switches occurring at a frequency of three or more were represented to better visualize the most common switches. Each column represents a biological line of treatment. Treatments are ordered according to frequency, the uppermost biologic in each line of treatment being the most frequent. Following lines of treatment once patients had discontinued their treatment or had been included in a clinical trial were not represented. Tables providing corresponding numbers and percentages are available in the supplementary material (Tables S1–S3). (b) Sankey diagram of switches from a biologic and treatment discontinuation by biologic drug class. *No other systemic treatment for 180 days or more. ^§Number of patients having switched to a biologic. Does not include patients who discontinued their biologic or participated in a clinical trial. Treatments are ordered according to frequency, the uppermost biologic in each line of treatment being the most frequent. Following lines of treatment once patients had discontinued their treatment or had been included in a clinical trial were not represented. [Colour figure can be viewed at wileyonlinelibrary.com]